KR102004959B9 - 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 - Google Patents
전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물Info
- Publication number
- KR102004959B9 KR102004959B9 KR1020180168596A KR20180168596A KR102004959B9 KR 102004959 B9 KR102004959 B9 KR 102004959B9 KR 1020180168596 A KR1020180168596 A KR 1020180168596A KR 20180168596 A KR20180168596 A KR 20180168596A KR 102004959 B9 KR102004959 B9 KR 102004959B9
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- treating
- preventing
- composition
- metastatic ovarian
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010014733 Endometrial cancer Diseases 0.000 title 1
- 206010014759 Endometrial neoplasm Diseases 0.000 title 1
- 206010033128 Ovarian cancer Diseases 0.000 title 1
- 206010061535 Ovarian neoplasm Diseases 0.000 title 1
- 230000001394 metastastic effect Effects 0.000 title 1
- 206010061289 metastatic neoplasm Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170002180 | 2017-01-06 | ||
| KR1020170002180 | 2017-01-06 | ||
| KR1020180002491A KR20180081675A (ko) | 2017-01-06 | 2018-01-08 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180002491A Division KR20180081675A (ko) | 2017-01-06 | 2018-01-08 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| KR20190001596A KR20190001596A (ko) | 2019-01-04 |
| KR102004959B1 KR102004959B1 (ko) | 2019-07-31 |
| KR102004959B9 true KR102004959B9 (ko) | 2023-04-17 |
Family
ID=63048777
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180002491A KR20180081675A (ko) | 2017-01-06 | 2018-01-08 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
| KR1020180143019A KR20180130090A (ko) | 2017-01-06 | 2018-11-19 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
| KR1020180168596A KR102004959B1 (ko) | 2017-01-06 | 2018-12-24 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
| KR1020190130945A KR20190124668A (ko) | 2017-01-06 | 2019-10-21 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
| KR1020200093338A KR102269666B1 (ko) | 2017-01-06 | 2020-07-27 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180002491A KR20180081675A (ko) | 2017-01-06 | 2018-01-08 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
| KR1020180143019A KR20180130090A (ko) | 2017-01-06 | 2018-11-19 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190130945A KR20190124668A (ko) | 2017-01-06 | 2019-10-21 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
| KR1020200093338A KR102269666B1 (ko) | 2017-01-06 | 2020-07-27 | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11779582B2 (ko) |
| EP (1) | EP3566705B1 (ko) |
| JP (1) | JP6831135B2 (ko) |
| KR (5) | KR20180081675A (ko) |
| CN (1) | CN110402143B (ko) |
| AU (1) | AU2018206372B2 (ko) |
| ES (1) | ES2932262T3 (ko) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102578970B1 (ko) | 2020-03-04 | 2023-09-15 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 난소암 예방, 개선 또는 치료 용도 |
| KR20230047879A (ko) | 2021-10-01 | 2023-04-10 | 연세대학교 산학협력단 | 탈리도마이드계 화합물을 포함하는 세포 부유성 억제용 조성물 및 암 전이 억제용 약학 조성물 |
| KR20230104055A (ko) * | 2021-12-30 | 2023-07-07 | 서울대학교산학협력단 | 유방암 세포주를 이용한 3차원 스페로이드 배양방법 및 이의 용도 |
| KR20230140678A (ko) | 2022-03-29 | 2023-10-10 | 중앙대학교 산학협력단 | Rbm15 억제제를 포함하는 유방암의 예방 또는 치료용 약제학적 조성물 |
| KR20240048415A (ko) | 2022-10-06 | 2024-04-15 | 성균관대학교산학협력단 | 알피눔이소플라본을 포함하는 난소암의 예방 또는 치료용 약제학적 조성물 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| WO2008098129A2 (en) * | 2007-02-07 | 2008-08-14 | Indiana University Research And Technology Corporation | Materials and methods for detecting and treating peritoneal ovarian tumor dissemination involving tissue transglutaminase |
| US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| US8753880B2 (en) * | 2011-07-08 | 2014-06-17 | University Of Rochester | Method of enriching stem and/or progenitor cells |
| AU2013241664B2 (en) * | 2012-03-30 | 2016-05-19 | Novartis Ag | FGFR inhibitor for use in the treatment of hypophosphatemic disorders |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| WO2014145751A2 (en) | 2013-03-15 | 2014-09-18 | The Translational Genomics Research Institute | Targeted therapies for cancer |
| EP3003377A1 (en) * | 2013-05-31 | 2016-04-13 | Novartis AG | Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer |
| KR102479696B1 (ko) * | 2014-03-26 | 2022-12-22 | 아스텍스 테라퓨틱스 리미티드 | Fgfr 억제제 및 igf1r 억제제의 조합물 |
| US9303069B2 (en) * | 2014-05-05 | 2016-04-05 | University Of Mississippi Medical Center | Peptides for treating cancer |
| US20170204187A1 (en) * | 2014-06-13 | 2017-07-20 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| KR20170090431A (ko) * | 2014-12-11 | 2017-08-07 | 바이엘 파마 악티엔게젤샤프트 | 범 ｆｇｆｒ 억제제의 용도 및 범 ｆｇｆｒ 억제제를 사용하는 치료에 대하여 적격인 암 환자를 확인하는 방법 |
| KR101732876B1 (ko) | 2016-01-08 | 2017-05-08 | 부산대학교 산학협력단 | 희귀 진세노사이드 CSH1(Rg6)을 유효성분으로 함유하는 항암제 내성 억제용 약학조성물 |
-
2018
- 2018-01-08 KR KR1020180002491A patent/KR20180081675A/ko active Application Filing
- 2018-01-08 JP JP2019537090A patent/JP6831135B2/ja active Active
- 2018-01-08 ES ES18736528T patent/ES2932262T3/es active Active
- 2018-01-08 CN CN201880016255.3A patent/CN110402143B/zh active Active
- 2018-01-08 US US16/476,220 patent/US11779582B2/en active Active
- 2018-01-08 EP EP18736528.3A patent/EP3566705B1/en active Active
- 2018-01-08 AU AU2018206372A patent/AU2018206372B2/en active Active
- 2018-11-19 KR KR1020180143019A patent/KR20180130090A/ko active Search and Examination
- 2018-12-24 KR KR1020180168596A patent/KR102004959B1/ko active IP Right Grant
-
2019
- 2019-10-21 KR KR1020190130945A patent/KR20190124668A/ko not_active Application Discontinuation
-
2020
- 2020-07-27 KR KR1020200093338A patent/KR102269666B1/ko active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20210137922A1 (en) | 2021-05-13 |
| KR20180130090A (ko) | 2018-12-06 |
| CN110402143A (zh) | 2019-11-01 |
| EP3566705A4 (en) | 2020-10-14 |
| KR20180081675A (ko) | 2018-07-17 |
| AU2018206372A1 (en) | 2019-08-08 |
| KR102269666B9 (ko) | 2023-04-17 |
| KR20200096185A (ko) | 2020-08-11 |
| US11779582B2 (en) | 2023-10-10 |
| KR102004959B1 (ko) | 2019-07-31 |
| AU2018206372B2 (en) | 2020-10-08 |
| CN110402143B (zh) | 2022-11-22 |
| KR102269666B1 (ko) | 2021-06-28 |
| EP3566705A1 (en) | 2019-11-13 |
| EP3566705B1 (en) | 2022-11-23 |
| KR20190124668A (ko) | 2019-11-05 |
| ES2932262T3 (es) | 2023-01-17 |
| JP2020515515A (ja) | 2020-05-28 |
| KR20190001596A (ko) | 2019-01-04 |
| JP6831135B2 (ja) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102269666B9 (ko) | 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물 | |
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| IL269150A (en) | Preparations and methods for the treatment of cancer | |
| IL263925A (en) | Methods of treating ovarian cancer | |
| IL275663A (en) | Cancer treatment methods | |
| HK1251493A1 (zh) | 使用pd-1軸結合拮抗劑和紫杉烷治療局部晚期或轉移性乳腺癌的方法 | |
| EP3359157A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METASTASIS AND RESISTANT TUMORS AND CANCERS | |
| IL268814A (en) | Preparations and methods for the treatment of cancer | |
| IL274837A (en) | Methods and preparations for the treatment of cancer | |
| KR102247795B9 (ko) | 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 | |
| EP3386522A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2-POSITIVE METASTATIC BREAST CANCER | |
| IL271019A (en) | Tinostemustine for the treatment of ovarian cysts | |
| IL269157A (en) | Preparations and methods for the treatment of cancer | |
| SG10202109335TA (en) | Inhibition of smarca2 for treatment of cancer | |
| EP3721906A4 (en) | USE OF PARP INHIBITOR TO TREAT CHEMOTHERAPY RESISTANT OVAR CANCER OR BREAST CANCER | |
| IL280587B (en) | Fluorocitidine derivatives and their preparations for use in cancer treatment | |
| IL276203A (en) | Compounds and methods for treating cancer | |
| SG11202005163PA (en) | Methods of treating cancer | |
| IL285028A (en) | Antiandrogens for the treatment of metastatic castration-sensitive prostate cancer | |
| IL272147A (en) | Methods and preparations for the treatment of cancer | |
| EP3572080A4 (en) | COMPOSITION INTENDED TO INHIBIT CANCER METASTASIS AND TREAT CANCER | |
| SG11202002123XA (en) | Compositions and methods for treating liver cancer | |
| FI3630112T3 (fi) | Regorafenibin ja nivolumabin yhdistelmä syövän hoidossa | |
| EP3579840C0 (en) | TREATMENT OF CANCER AND INHIBITION OF METASTASIS | |
| ZA201802268B (en) | Methods and compositions for preventing or treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| G170 | Re-publication after modification of scope of protection [patent] |